Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

23 Apr 2020

Abstract excerpt

Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half of patients under targeted compounds (TKI) and facilitates use of regional therapies that can prolong survival. In order to characterize OPD in immunotherapy (IO)-treated NSCLC, we analyzed the failure pattern under PD-1/PD-L1 inhibitors (n = 297) or chemoimmunotherapy (n = 75). Under IO monotherapy, OPD was more frequent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32340408
DOI: 10.3390/cancers12041046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 InhibitorsPMID 32340408Read ↗

Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity.Semantic proximity Read ↗

Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, KEAP1/STK11 co-mutated metastatic NSCLC.Semantic proximity Read ↗

Progression phenotypes to anti-PD-(L)1 therapy and subsequent management of patients with metastatic NSCLC: A real-world cohort study.Semantic proximity Read ↗

The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.Semantic proximity Read ↗

Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease and Oligo-Progressive Disease in EGFR-Mutated Non-Small Cell Lung CancerSemantic proximity Read ↗

Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment.Semantic proximity Read ↗

SBRT for oligoprogressive oncogene addicted NSCLC.Semantic proximity Read ↗

Real-world survival outcomes to first-line chemoimmunotherapy and biomarker analysis in extensive-stage small-cell lung cancerSemantic proximity Read ↗

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?Semantic proximity Read ↗

T cell invigoration is associated with the clinical response to anti-PD-1 based immunotherapy in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.